RxDoctor Payments Data

Greg Parker

Family · Gulfport, MSNPI 1073574687

Payments from drug & device makers

$6,750in general payments, 2019–2025

Across 444 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Lilly USA, LLC$612
  • Abbott$547
  • Amgen$516
  • Sumitomo Pharma America, Inc.$458
  • Novo Nordisk$415
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,66499%
  • Education$861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,750 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$69,294
Medicare patients
220
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$184,697
TrulicityDulaglutide61$74,078
JardianceEmpagliflozin64$62,288
JanuviaSitagliptin Phosphate52$61,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$57,898
LinzessLinaclotide33$36,085
MounjaroTirzepatide27$30,444
FarxigaDapagliflozin Propanediol29$23,144
Tresiba Flextouch U-200Insulin Degludec18$16,407
XareltoRivaroxaban11$15,432
NexlizetBempedoic Acid/Ezetimibe23$12,072
EntrestoSacubitril/Valsartan11$11,450
Novolog FlexpenInsulin Aspart23$9,407
GemtesaVibegron16$9,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$415$184,697173 claims
Lilly USA, LLCTrulicity, Mounjaro$612$104,52288 claims
Boehringer IngelheimJardiance$150$62,28864 claims
MerckJanuvia$128$61,42452 claims
GSKTrelegy Ellipta$1,078$57,89892 claims
AbbVieLinzess, Synthroid$243$39,26661 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$379$35,29555 claims
Johnson & JohnsonXarelto$69$15,43211 claims
Esperion Therapeutics, Inc.Nexlizet$19$12,07223 claims
NovartisEntresto$155$11,45011 claims
Sumitomo Pharma America, Inc.Gemtesa$458$9,22616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →